Drug intelligence / Profile preview

ZK063

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ZK063 is a humanized monoclonal antibody being developed by Lee's Pharmaceutical for the treatment of osteogenesis imperfecta (OI). The drug functions as a transforming growth factor beta (TGF-β) antagonist. Research has shown that excessive TGF-β signaling is a key driver of the bone defects observed in OI, a genetic disorder characterized by bone fragility and low bone mass. By inhibiting TGF-β, ZK063 is intended to reduce excessive bone resorption and promote bone formation, thereby improving bone mineral density and reducing fracture risk. As of 2024, the asset remains in the preclinical stage of development.

Other names: ZK063ZK-063ZK 063

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on ZK063.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK063.

Explore the full profile